U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H27O2.Na
Molecular Weight 322.4169
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM DEHYDROABIETATE

SMILES

[Na+].CC(C)C1=CC2=C(C=C1)[C@@]3(C)CCC[C@](C)([C@@H]3CC2)C([O-])=O

InChI

InChIKey=ZCSNFGCDVJGPDD-YGJXXQMASA-M
InChI=1S/C20H28O2.Na/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22;/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22);/q;+1/p-1/t17-,19-,20-;/m1./s1

HIDE SMILES / InChI

Description

Dehydroabietic acid (DHA or DAA), a diterpene, is obtained from Commiphora oppbalsamum. DHA has potential as treatment for obesity and metabolic syndrome, obese diabetic KK-Ay mice treated with DHA showed decreased plasma glucose, insulin, and triglyceride levels. It has been reported that DHA inhibits the production of proinfammatory mediators such as TNF-α in macrophages and adipocytes and causes endothelium-dependent relaxation of pulmonary artery via PI3K/Akt-eNOS signaling pathway. Also was shown, that DHA could reverse several cell responses stimulated by TNF-α, including the activation of FOXO1 and the TGF-β1/Smad3 signaling pathway. Thus, DAA could be useful in improving the diabetic wound healing.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
The back (2*8 cm2) of each mouse was shaved with surgical clippers and treated topically with DMBA (100 mg, 390 nmol) in acetone as an initiation treatment. For group 1(positive control group), 1 week after the initiation with DMBA, papilloma formation was promoted twice weekly by the application of TPA (1 mg, 1.7nmol) in acetone on the skin. Groups III received a topical application of test samples, dehydroabietic acid (4), (85nmol) in acetone 1h before the promotion treatment. The percentage of papilloma bearers and the average number of papillomas per mouse were observed weekly for 20 weeks. Dehydroabietic acid exhibited high activity in the in vivo anti-tumor-promoting test.
Route of Administration: Topical
In Vitro Use Guide
Microtiter plates containing 2.5 mkL per well of 2-fold serial dilutions of each antimicrobial agent were inoculated with 100 mkL of bacterial suspension to yield the appropriate density ((1-5) * 10-5 CFU/mL). The plates were incubated for 18 h at 35 °C in ambient air. The MIC was defined as the lowest concentration of a compound that completely inhibited the growth of the organism